The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Acadia Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $150 Million
Nov 05, 2024•over 1 year ago
Contract Type
agreement
San Diego
Description
Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The PRV was granted in March 2023 following the approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ for the treatment of Rett syndrome. Acadia plans to invest the proceeds from the sale to support its commercial operations, R&D programs, and future business development.
Company Information
Company
Acadia Pharmaceuticals
Location
San Diego, California, United States
About
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.
San Diego